Skip to main content

Infections, Gram-Positive Bacterial

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Cumberland Pharmaceuticals
2 programs
2
TelavancinPhase 21 trial
TelavancinPhase 21 trial
Active Trials
NCT00061633Completed169Est. Jan 2004
NCT00077675Completed201Est. Sep 2004

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Cumberland PharmaceuticalsTelavancin
Cumberland PharmaceuticalsTelavancin

Clinical Trials (2)

Total enrollment: 370 patients across 2 trials

NCT00077675Cumberland PharmaceuticalsTelavancin

Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

Start: Feb 2004Est. completion: Sep 2004201 patients
Phase 2Completed
NCT00061633Cumberland PharmaceuticalsTelavancin

Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

Start: Jun 2003Est. completion: Jan 2004169 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.